Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:21 PM
Ignite Modification Date:
2025-12-24 @ 9:21 PM
NCT ID:
NCT05609604
Eligibility Criteria:
Inclusion Criteria:
* Men and women 18 to 80 years of age
* Body mass index \> 30 kg/m2
Exclusion Criteria:
* Current participation in any other concurrent clinical trials or previous participation within 30 days before the screening visit
* Pregnancy or premenopausal women who are trying to be pregnant
* Patients who are incompetent to give consent
* Obesity due to a known secondary cause (Cushing's syndrome, hypothyroidism, etc) or a history of weight loss surgery
* Have taken any of the following medications within the past 3 months:
* phentermine, naltrexone, bupropion, topiratmate, lorcaserin, phendimetrazine, methamphetamine, benzphetamine, diethylpropion
* Any contraindication to receive transcranial direct current stimulation (tDCS):
* Personal or family history of seizures, epilepsy or other unexplained loss of consciousness.
* Current or past history of skin disease or damaged skin on the scalp at the site of stimulation (i.e. eczema, skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.).
* Prior neurosurgical procedure or radiation.
* Known diagnosis of brain lesions, such as tumor, stroke or multiple sclerosis
* Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, Transcutaneous Electrical Nerve Stimulation unit, ventriculo-peritoneal shunt or any metallic implant on the head.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT05609604
Study Brief:
Protocol Section:
NCT05609604